BioCentury | Sep 8, 2014
Company News

Kiadis Pharma management update

...the Netherlands Business: Cancer, Transplant, Gene/Cell therapy Hired: Jeroen Rovers as CMO, formerly CMO of Ceronco Biosciences B.V. WIR...
BioCentury | Apr 16, 2012
Emerging Company Profile

Ceronco: Gateway into the cell

...doxorubicin rely on passive diffusion to enter the cancer cell, which Rovers said limits efficacy. Ceronco...
...Netherlands Cancer Institute showing the cancer cell membrane can be modulated using short chain sphingolipids. Ceronco's...
...cholesterol, and these short chain lipids have their effect specifically on cholesterol-rich domains," he said. Ceronco...
BioCentury | Apr 16, 2012
Clinical News

Ceronco Biosciences preclinical data

...glucosylceramide . Data were presented at the American Association for Cancer Research meeting in Chicago. Ceronco...
Items per page:
1 - 3 of 3
BioCentury | Sep 8, 2014
Company News

Kiadis Pharma management update

...the Netherlands Business: Cancer, Transplant, Gene/Cell therapy Hired: Jeroen Rovers as CMO, formerly CMO of Ceronco Biosciences B.V. WIR...
BioCentury | Apr 16, 2012
Emerging Company Profile

Ceronco: Gateway into the cell

...doxorubicin rely on passive diffusion to enter the cancer cell, which Rovers said limits efficacy. Ceronco...
...Netherlands Cancer Institute showing the cancer cell membrane can be modulated using short chain sphingolipids. Ceronco's...
...cholesterol, and these short chain lipids have their effect specifically on cholesterol-rich domains," he said. Ceronco...
BioCentury | Apr 16, 2012
Clinical News

Ceronco Biosciences preclinical data

...glucosylceramide . Data were presented at the American Association for Cancer Research meeting in Chicago. Ceronco...
Items per page:
1 - 3 of 3